Dyne Therapeutics (DYN) News Today

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares were mixed today amid a flurry of analyst updates and legal developments.

• Positive Sentiment: HC Wainwright raised its Q3 2025 EPS estimate to ($0.73) from ($1.06) and reaffirmed a Buy rating with a $38 price target. HC Wainwright Has Optimistic Outlook of DYN Q3 Earnings
• Positive Sentiment: Zacks notes that analysts’ consensus price targets imply a potential 285.6% upside for DYN shares. Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
• Positive Sentiment: Royal Bank of Canada initiated coverage with a $23.00 price target on DYN shares. Dyne Therapeutics (NASDAQ:DYN) Given New $23.00 Price Target at Royal Bank Of Canada
• Positive Sentiment: Raymond James Financial awarded DYN an “Outperform” rating. Dyne Therapeutics (NASDAQ:DYN) Receives "Outperform" Rating from Raymond James Financial
• Neutral Sentiment: Chardan Capital trimmed its FY2025 EPS forecast to ($3.47) from ($3.40) but maintained a Buy rating and a $38 target. Chardan Capital FY2025 EPS Estimates Reduction
• Negative Sentiment: Stifel Nicolaus slashed its DYN price target from $66 to $36, although it kept a Buy rating. Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $36.00 by Analysts at Stifel Nicolaus
• Negative Sentiment: Pomerantz LLP launched a securities investigation into Dyne Therapeutics on behalf of investors. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Investors are weighing optimistic EPS revisions and bullish coverage initiations against earnings downgrades, a steep target‐price cut from Stifel Nicolaus, and legal headwinds from the Pomerantz investigation.